Thymulin, a hormone produced by the thymus gland, reduces systemic inflammation in aging mice and enhances the effectiveness of cancer treatments. The research identifies thymulin as a circulating factor capable of modulating age-related immune dysfunction independently of full immune system rejuvenation.
Key Points
- Thymulin suppresses pro-inflammatory cell activation in aged mice
- Age drives systemic inflammation more than tumor presence alone
- Thymulin treatment improved cancer therapy efficacy in older animals
Longevity Analysis
This work addresses a fundamental mechanism linking immune aging to cancer progression and treatment resistance. Rather than attempting complete immune restoration, the research demonstrates that targeted modulation of a single circulating factor can restore immune competence sufficient to improve therapeutic outcomes. This approach is clinically relevant because thymulin activity declines naturally with age and in cancer patients, making it a measurable biomarker and a candidate for pharmacological intervention. The findings suggest that restoring the signaling capacity of aging immune tissues—rather than replacing them entirely—may be sufficient to address inflammaging and its downstream consequences.
Original published by LifeSpan.io, by Anna Drangowska-Way.